Table 2.

Subgroup analysis of association of PD-L1 expression and OS and PFS in melanoma

Factors	No. of studies	No. of patients	Effects model	HR (95% CI)	p	Heterogeneity
						I2 (%)	P
Overall survival
Total	10	889	Random	0.93 (0.57–1.52)	0.781	77.8	< 0.001
Ethnicity
Asian	2	125	Fixed	1.21 (0.64–2.31)	0.553	0	0.335
Caucasian	8	764	Random	0.85 (0.48–1.52)	0.59	82.2	< 0.001
Stage
Metastatic	7	741	Random	0.89 (0.49–1.61)	0.704	84.4	< 0.001
Mixed	3	148	Fixed	1.11 (0.60–2.06)	0.740	0	0.365
Sample size
< 80	5	269	Fixed	0.77 (0.52–1.16)	0.211	27.1	0.241
≥ 80	5	620	Random	1.08 (0.52–2.27)	0.830	87.9	< 0.001
Cut–off value
> 5%	5	572	Random	1.37 (0.80–2.36)	0.080	77.2	0.002
> 1% and others	5	317	Random	0.53 (0.26–1.08)	0.252	58.3	0.048
Treatment
ICIs	3	393	Random	0.62 (0.27–1.40)	0.252	79.5	0.008
BRAFi	2	138	Random	1.47 (0.08–27.21)	0.797	93.6	< 0.001
Surgery	2	112	Fixed	0.91 (0.44–1.85)	0.666	0	0.380
Mixed	3	246	Fixed	1.06 (0.80–1.41)	0.789	44.7	0.164
Progression-free survival
Total	8	565	Random	0.82 (0.43–1.54)	0.535	75.4	< 0.001
Ethnicity
Asian	3	204	Fixed	0.93 (0.57–1.50)	0.756	44.9	0.163
Caucasian	5	361	Random	0.79 (0.32–2.08)	0.629	83.9	< 0.001
Stage
Metastatic	4	317	Random	0.88 (0.26–3.03)	0.838	85.4	< 0.001
Mixed	4	248	Random	0.75 (0.40–1.42)	0.380	52.2	0.099
Sample size
< 80	5	254	Random	0.60 (0.30–1.21)	0.153	50.6	0.088
≥ 80	3	311	Random	1.30 (0.42–4.01)	0.654	88.2	< 0.001
Cut-off value
> 5%	4	348	Random	1.00 (0.34–2.90)	1	84.6	< 0.001
> 1% and others	4	217	Random	0.66 (0.32–1.39)	0.274	56	0.078
Treatment
ICIs	2	179	Fixed	0.58 (0.30–1.13)	0.110	0	0.321
BRAFi	2	138	Random	1.56 (0.20–11.84)	0.668	91.5	0.001
Surgery	3	190	Random	0.74 (0.30–1.84)	0.515	67.2	0.047
Mixed	1	58	–	0.69 (0.30–1.59)	0.383	–	–

ICIs immune checkpoint inhibitors, BRAFi BRAF inhibitor